Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Zoster Vaccine Recombinant, Adjuvanted; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meningitis, Meningococcal Infection
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 15 Years to 23 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 84 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 211 Days
Enrollment: 3,230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 111
States / cities: Bessemer, Alabama • Birmingham, Alabama • Fayetteville, Arkansas + 74 more

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 2 more

Conditions: Healthy
Interventions: Ad26.Filo, MVA-BN-Filo, Ad26.ZEBOV, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Alzheimer's Disease
Interventions: CAD106, Placebo, Alum, MF59; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Up to 85 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more

Conditions: Diarrhea
Interventions: CssBA, dmLT; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Influenza, Human
Interventions: Exercise; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 65 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: VAX161 [STF2.HA5 H5N1]; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more

Conditions: Carcinoma, Renal Cell
Interventions: TroVax® (Immunological Vaccine Therapy), Interferon-alpha; Biological · Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Moderna RSV vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 60 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Seasonal Influenza
Interventions: mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 698 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 22
States / cities: Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more

Conditions: Aging
Interventions: vaccine; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Tetanus, Acellular Pertussis, Diphtheria
Interventions: SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 4,209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 24
States / cities: Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more

Conditions: COVID-19 Prevention
Interventions: Ad26.COV2.S, Placebo, Influenza Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Norovirus Prevention
Interventions: Norovirus Bivalent VLP Vaccine, Placebo (Saline); Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more

Conditions: Prostate Cancer
Interventions: MUC_1; Drug
Lead sponsor: Olivera Finn; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 83 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: COVID-19
Interventions: SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more

Conditions: Monkeypox
Interventions: BNT166a; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: San Diego, California • Kansas City, Missouri • Knoxville, Tennessee + 1 more

Search by objective public record fields.

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

Resistance Exercise to Improve Flu Vaccine for Older Adults

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

Systems Biological Analysis of Immune Responses to RSV Vaccine

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

Effects of Aging on Primary and Secondary Vaccine Responses

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines